These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. SV40 virus-like particles as an effective delivery system and its application to a vaccine carrier. Kawano M; Matsui M; Handa H Expert Rev Vaccines; 2013 Feb; 12(2):199-210. PubMed ID: 23414410 [TBL] [Abstract][Full Text] [Related]
10. Influenza virosomes as an efficient system for adjuvanted vaccine delivery. Glück R; Moser C; Metcalfe IC Expert Opin Biol Ther; 2004 Jul; 4(7):1139-45. PubMed ID: 15268680 [TBL] [Abstract][Full Text] [Related]
11. Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity. de Vries JJ; Bungener L; Ter Veer W; van Alphen L; van der Ley P; Wilschut J; Huckriede A Vaccine; 2009 Feb; 27(6):947-55. PubMed ID: 19059296 [TBL] [Abstract][Full Text] [Related]
12. Adjuvant and antigen delivery properties of virosomes. Glück R; Burri KG; Metcalfe I Curr Drug Deliv; 2005 Oct; 2(4):395-400. PubMed ID: 16305442 [TBL] [Abstract][Full Text] [Related]
13. Liposomal adjuvants for human vaccines. Alving CR; Beck Z; Matyas GR; Rao M Expert Opin Drug Deliv; 2016 Jun; 13(6):807-16. PubMed ID: 26866300 [TBL] [Abstract][Full Text] [Related]
14. European union regulatory developments for new vaccine adjuvants and delivery systems. Sesardic D; Dobbelaer R Vaccine; 2004 Jun; 22(19):2452-6. PubMed ID: 15193409 [TBL] [Abstract][Full Text] [Related]
16. Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells. Amacker M; Engler O; Kammer AR; Vadrucci S; Oberholzer D; Cerny A; Zurbriggen R Int Immunol; 2005 Jun; 17(6):695-704. PubMed ID: 15843436 [TBL] [Abstract][Full Text] [Related]
17. Adjuvant formulations for virus-like particle (VLP) based vaccines. Cimica V; Galarza JM Clin Immunol; 2017 Oct; 183():99-108. PubMed ID: 28780375 [TBL] [Abstract][Full Text] [Related]
18. Platform for the generation of oral vaccines based on protozoan surface proteins. Serradell MDC; Rupil LL; Luján HD Medicina (B Aires); 2019; 79(Spec 6/1):559-563. PubMed ID: 31864226 [TBL] [Abstract][Full Text] [Related]